Industry Roundup: Cardinal Buys Harvard Drug, Similac Lawsuit, State AGs Question Supplement Oversight
This article was originally published in The Tan Sheet
Cardinal acquires Harvard Drug; Similac ‘organic’ claims deceptive – complaint; N.Y., Ind. criticize supplement regulatory flexibility; Amway headquarters manufacturing site opens; and more news in brief.
You may also be interested in...
Warning letter a year after recall; spiked supplement total climbs; FTC-USDA "organic" roundtable; and FTC ISO ICA for Herbalife.
In addition to Major and Rugby supplement brands marketed by Cardinal Health subsidiary Harvard Health Group, PharmaTech's recall includes products it makes for the BProtected, Renew HC and Cytodetox brands.
Watson Pharmaceuticals sells OTC business Rugby Laboratories to Harvard Drug Group, which operates Major Pharmaceuticals manufacturing. Watson divests a business that accounted for a small part of the private label OTC market, but keeps its pending ANDAs for guaifenesin expectorants and its smoking-cessation generics.